Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
Keros Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are...
Upcoming Exon 51 Skipping Therapies for the Treatment of Duchenne Muscular Dystrophy
Duchenne Exon 51 skipping therapies are innovative treatments aimed at addressing the genetic mutation responsible for Duchenne muscular dystrophy (DMD). By skipping exon 51...
Shanghai Jiao Tong University School of Medicine Begins Clinical Trials of LE051 Exon 51 Skipping Therapy
The purpose of LE051 study is to evaluate the safety, tolerability, and efficacy of LE051 intravenous therapy in DMD patients treated with exon 51...
Fn14 Protein May Protect Muscle Stem Cells, Offering Promise for Development of Duchenne Treatments
For millions of people, losing muscle means losing their freedom as well as their strength. Muscle loss, whether from Duchenne muscular dystrophy, aging, or...
Significant Improvements Seen in 3 Children Receiving Dystrogen Therapeutics’ DT-DEC01 Cell Therapy
In non-ambulatory individuals with Duchenne muscular dystrophy (DMD), DT-DEC01 (Dystrogen Therapeutics), an experimental dystrophin expressing chimeric (DEC) cell treatment, was found to be safe...